UBS initiated coverage of Fulgent Genetics with a Neutral rating and $35 price target. Fulgent can continue to grow its next-generation sequencing based testing business, but the growth will decelerate going forward, the analyst tells investors in a research note. Further, the company’s commodity oncology / pathology businesses could dampen growth momentum given the lower growth trends in those markets and limited visibility, says the firm.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FLGT:
- Options Volatility and Implied Earnings Moves Today, November 03, 2023
- Fulgent Genetics backs FY23 EPS view (95c), consensus ($1.09)
- Fulgent Genetics reports Q3 EPS (39c), consensus (33c)
- FLGT Earnings this Week: How Will it Perform?
- Fulgent Genetics price target lowered to $28 from $37 at Piper Sandler
